PetMed Express
PETS
86 hedge funds and large institutions have $43.3M invested in PetMed Express in 2024 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 23 closing their positions.
24% more capital invested
Capital invested by funds: $35M → $43.3M (+$8.31M)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
2.67% less ownership
Funds ownership: 46.11% → 43.44% (-2.7%)
8% less funds holding
Funds holding: 93 → 86 (-7)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
78% less call options, than puts
Call options by funds: $1.12M | Put options by funds: $5.07M
Top Buyers
| 1 |
MC
Metavasi Capital
Larchmont,
New York
|
+$521K |
| 2 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
+$506K |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$504K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$396K |
| 5 |
JP Morgan Chase
New York
|
+$391K |
Top Sellers
PETS Hedge Fund Activity: Q4 2024 in Review
86 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in PetMed Express (PETS) for Q4 2024, worth a combined $43.3M — up 24% from $35M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of PETS and 17 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 27 added.
The largest buyer was Metavasi Capital, adding an estimated $521K. The largest seller was D.E. Shaw & Co, cutting an estimated $700K.
- 86 institutional investors held PetMed Express (PETS) as of Q4 2024, down from 93 in Q3 2024.
- Funds reported $43.3M of PetMed Express stock for Q4 2024, up 24% quarter-over-quarter.
- 17 funds opened new PetMed Express positions in Q4 2024 and 23 closed out, a net change of -6 holders.
- The largest PetMed Express buyer in Q4 2024 was Metavasi Capital, an estimated $521K added.
- The largest PetMed Express seller in Q4 2024 was D.E. Shaw & Co, an estimated $700K sold.
Based on aggregated 13F filings for Q4 2024.